Call for Papers: Antibody-Drug Conjugates for Cancer Treatment
Antibody-drug conjugates (ADCs) represent a groundbreaking class of therapies that harness the precision of monoclonal antibodies alongside the potent cytotoxic agents, aiming to mitigate side effects and achieve targeted delivery to tumor cells. Meticulously crafted ADCs exhibit the ability to precisely direct therapeutic payloads, yielding heightened effectiveness, a broader therapeutic range, and extended circulation compared to conventional chemotherapy agents. The US Food and Drug Administration (FDA) has greenlit the marketing of fifteen ADCs, while over 220 ADCs are presently undergoing clinical trials. Beyond this, research is actively exploring bispecific ADCs, dual payload ADCs, and immune-stimulating ADCs (ISAC) in pursuit of enhanced anti-tumor efficacy. Hence, the Antibody Therapeutics journal is currently initiating a special issue/collection centered around ADCs for cancer treatment.
This special issue/collection invites submissions of research and/or review papers on various aspects of ADCs, with suggested topics including but not limited to:
- Development of novel ADCs
- Development of ADCs targeting novel targets
- Conjugation technologies of ADCs
- Research and development progress of ADC payloads
- Linker chemistry of ADCs
- Bispecific ADCs
- ADCs with dual payloads
- Immune-stimulating ADCs
- Radionuclide-Drug Conjugates (RDCs)
- Antibody-Oligonucleotide Conjugates (AOC)
The special issue/collection welcomes manuscript submission via the Antibody Therapeutics online submission site. Please view our author guidelines for further information on manuscript preparation and submission.
The deadline for submitting manuscripts for this special issue is August 31, 2024. Please contact [email protected] if there are any questions.
Antibody Therapeutics is published by Oxford University Press. As a peer-reviewed and open access journal, Antibody Therapeutics provides a forum for the publication of the latest advances and challenges in the discovery, research, development, and methodology of therapeutic antibodies for the global scientific community. The journal has been indexed by leading literature databases, such as Scopus (2023 CiteScore: 8.7) and PubMed.
Guest editors of this special issue are:
- Victor S. Goldmacher, PhD, Co-founder and CSO of ImmuVia
- Chaohong (Mary) Hu, PhD, Co-CEO of Lepu Biopharma Co Ltd, and Founder and CEO of Shanghai Miracogen Inc.
